Excellus BCBS

Does Excellus BCBS cover Zepbound?

Quick answer · Weight Loss

Excellus BCBS covers Zepbound for weight loss with prior authorization on Employer / Commercial Insurance and ACA Marketplace.

  • Employer / Commercial Insurance: Covered with requirements. BMI of 40 or higher
  • ACA Marketplace: Covered with requirements. BMI of 40 or higher

Last verified June 5, 2026. Source: weight-management-policy-pdf. How we verify this data →

Check your card for your exact plan →

Zepbound for Weight Loss

What Excellus BCBS requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Covered with requirements

What you need to qualify

  • Age 18 and older
  • BMI of 40 or higher
  • BMI of 35 or higher with a weight-related condition (CVD, dyslipidemia, gallstones, gynecological_abnormalities, hypercholesterolemia, HTN, metabolic_syndrome, MAFLD, pulmonary_hypoventilation, OSA, stress_incontinence, T2DM, and weight_bearing_joint_arthropathy)
  • BMI of 25 or higher for patients of Asian descent
  • 3 months of a documented diet and exercise program
  • Prior trial of another GLP-1 medication (Foundayo) for at least 180 days

Qualification pathways

You can qualify through any one of these.

Adult weight loss — Class III obesity

All of:

  • Age ≥ 18 years
  • BMI ≥ 40 kg/m² (Class III obesity)
  • Enrolled in qualified comprehensive weight management program for ≥3 consecutive months
  • Documentation of trial and failure of Foundayo (or documented contraindication to Foundayo)
  • Not used in combination with any other GIP and/or GLP-1 receptor agonist
  • Not used in combination with other weight loss drugs (Rx, OTC, or herbal)
  • Coverage criteria apply to Zepbound pens only (vials and Kwikpens are not a covered benefit)

Adult weight loss — Class II obesity with comorbidity

All of:

  • Age ≥ 18 years
  • BMI 35–39.9 kg/m² (Class II obesity)
  • Enrolled in qualified comprehensive weight management program for ≥3 consecutive months
  • Documentation of trial and failure of Foundayo (or documented contraindication to Foundayo)
  • Not used in combination with any other GIP and/or GLP-1 receptor agonist
  • Not used in combination with other weight loss drugs (Rx, OTC, or herbal)
  • Coverage criteria apply to Zepbound pens only (vials and Kwikpens are not a covered benefit)

Plus any one of:

  • Cardiovascular Disease
  • Dyslipidemia (high LDL, TG, or low HDL)
  • Gallstones
  • Gynecological abnormalities
  • Hypercholesterolemia
  • Hypertension
  • Metabolic Syndrome
  • MAFLD
  • Pulmonary Hypoventilation
  • Obstructive Sleep Apnea
  • Stress Incontinence
  • Type 2 Diabetes
  • Weight-Bearing Joint Arthropathy

Documentation to bring

  • Baseline BMI and weight documentation
  • Height documentation
  • Documentation of current enrollment in qualified comprehensive weight management program for ≥3 consecutive months
  • Proof of current and prior participation in comprehensive weight management program (receipt or certificate and dietary/exercise logs)
  • Documentation of trial and failure of Foundayo OR documented contraindication to Foundayo
  • Progress notes documenting clinical status at time drug was originally initiated (weight, height, BMI, comorbid conditions)

Quantity limits

  • 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg — 2 mL (4 pens) per 28 days; Maximum 14 twenty-eight-day supplies OR 5 eighty-four-day supplies per 365 days; first 6 fills for new starts limited to 28-day supply or less; 2.5mg strength limited to 2mL per 365 days (titration only, not for chronic use beyond initial 4-week titration period) (84-day)

Approval and renewal

  • Initial approval: 7 months
  • Renewal: every 6 months
  • To renew, the plan looks for at least 5% weight loss from the starting weight, At initial recertification (7 months): physician-verified weight loss of ≥5% of initial weight. For ongoing 6-month recertifications: must have maintained ≥5% weight loss OR continued to lose weight; current BMI must not be less than 18.5 kg/m². Patient must be utilizing maintenance dose (5mg, 7.5mg, 10mg, 12.5mg, or 15mg). For patients unable to tolerate approved maintenance doses, minimum of 5mg once weekly will be covered. Continued comprehensive weight management program enrollment required, at least 17 weeks on therapy before the first renewal, and staying on a maintenance dose of at least 5 mg. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

  • Zepbound vials and Kwikpens are not a covered benefit (patients may obtain through LillyDirect access program)
  • Non-FDA approved diagnoses not covered
  • Combination with other GIP and/or GLP-1 receptor agonists not approved (Exenatide, Victoza, Ozempic, Rybelsus, Trulicity, Mounjaro)
  • Combination with any other weight loss drugs (Rx, OTC, or herbal) not approved
  • 2.5mg strength limited to initial 4-week titration only — not covered for chronic use
  • Organic causes of obesity (e.g., hypothyroidism) must be excluded before prescribing
  • Demonstration of failed efficacy (not meeting continuation criteria) precludes future coverage of same drug

Exceptions

  • New York: All utilization management requirements compliant with applicable New York State insurance laws and regulations

Policy note: BMI thresholds may be adjusted for Asian population on case-by-case basis (BMI ≥25 kg/m² suggests clinical obesity). Documentation must reflect clinical status at time drug was originally initiated. Patients not treated in past 4 months considered new to therapy. OSA indication is integrated into existing weight management criteria (see OSA entry). Annual GLP-1 day-supply limits apply cumulatively across all products. Off-label use (e.g., pre-diabetes extension of SURMOUNT-1) subject to weight management criteria if efficacy is not independent of weight loss.

verified June 5, 2026 · source: weight-management-policy-pdf

ACA Marketplace

Covered with requirements

What you need to qualify

  • Age 18 and older
  • BMI of 40 or higher
  • BMI of 35 or higher with a weight-related condition (CVD, dyslipidemia, gallstones, gynecological_abnormalities, hypercholesterolemia, HTN, metabolic_syndrome, MAFLD, pulmonary_hypoventilation, OSA, stress_incontinence, T2DM, and weight_bearing_joint_arthropathy)
  • BMI of 25 or higher for patients of Asian descent
  • 3 months of a documented diet and exercise program
  • Prior trial of another GLP-1 medication (Foundayo) for at least 180 days

Qualification pathways

You can qualify through any one of these.

Adult weight loss — Class III obesity

All of:

  • Age ≥ 18 years
  • BMI ≥ 40 kg/m² (Class III obesity)
  • Enrolled in qualified comprehensive weight management program for ≥3 consecutive months
  • Documentation of trial and failure of Foundayo (or documented contraindication to Foundayo)
  • Not used in combination with any other GIP and/or GLP-1 receptor agonist
  • Not used in combination with other weight loss drugs (Rx, OTC, or herbal)
  • Coverage criteria apply to Zepbound pens only (vials and Kwikpens are not a covered benefit)

Adult weight loss — Class II obesity with comorbidity

All of:

  • Age ≥ 18 years
  • BMI 35–39.9 kg/m² (Class II obesity)
  • Enrolled in qualified comprehensive weight management program for ≥3 consecutive months
  • Documentation of trial and failure of Foundayo (or documented contraindication to Foundayo)
  • Not used in combination with any other GIP and/or GLP-1 receptor agonist
  • Not used in combination with other weight loss drugs (Rx, OTC, or herbal)
  • Coverage criteria apply to Zepbound pens only (vials and Kwikpens are not a covered benefit)

Plus any one of:

  • Cardiovascular Disease
  • Dyslipidemia (high LDL, TG, or low HDL)
  • Gallstones
  • Gynecological abnormalities
  • Hypercholesterolemia
  • Hypertension
  • Metabolic Syndrome
  • MAFLD
  • Pulmonary Hypoventilation
  • Obstructive Sleep Apnea
  • Stress Incontinence
  • Type 2 Diabetes
  • Weight-Bearing Joint Arthropathy

Documentation to bring

  • Baseline BMI and weight documentation
  • Height documentation
  • Documentation of current enrollment in qualified comprehensive weight management program for ≥3 consecutive months
  • Proof of current and prior participation in comprehensive weight management program (receipt or certificate and dietary/exercise logs)
  • Documentation of trial and failure of Foundayo OR documented contraindication to Foundayo
  • Progress notes documenting clinical status at time drug was originally initiated (weight, height, BMI, comorbid conditions)

Quantity limits

  • 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg — 2 mL (4 pens) per 28 days; Maximum 14 twenty-eight-day supplies OR 5 eighty-four-day supplies per 365 days; first 6 fills for new starts limited to 28-day supply or less; 2.5mg strength limited to 2mL per 365 days (titration only, not for chronic use beyond initial 4-week titration period) (84-day)

Approval and renewal

  • Initial approval: 7 months
  • Renewal: every 6 months
  • To renew, the plan looks for at least 5% weight loss from the starting weight, At initial recertification (7 months): physician-verified weight loss of ≥5% of initial weight. For ongoing 6-month recertifications: must have maintained ≥5% weight loss OR continued to lose weight; current BMI must not be less than 18.5 kg/m². Patient must be utilizing maintenance dose (5mg, 7.5mg, 10mg, 12.5mg, or 15mg). For patients unable to tolerate approved maintenance doses, minimum of 5mg once weekly will be covered. Continued comprehensive weight management program enrollment required, at least 17 weeks on therapy before the first renewal, and staying on a maintenance dose of at least 5 mg. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

  • Zepbound vials and Kwikpens are not a covered benefit (patients may obtain through LillyDirect access program)
  • Non-FDA approved diagnoses not covered
  • Combination with other GIP and/or GLP-1 receptor agonists not approved (Exenatide, Victoza, Ozempic, Rybelsus, Trulicity, Mounjaro)
  • Combination with any other weight loss drugs (Rx, OTC, or herbal) not approved
  • 2.5mg strength limited to initial 4-week titration only — not covered for chronic use
  • Organic causes of obesity (e.g., hypothyroidism) must be excluded before prescribing
  • Demonstration of failed efficacy (not meeting continuation criteria) precludes future coverage of same drug

Exceptions

  • New York: All utilization management requirements compliant with applicable New York State insurance laws and regulations

Policy note: BMI thresholds may be adjusted for Asian population on case-by-case basis (BMI ≥25 kg/m² suggests clinical obesity). Documentation must reflect clinical status at time drug was originally initiated. Patients not treated in past 4 months considered new to therapy. OSA indication is integrated into existing weight management criteria (see OSA entry). Annual GLP-1 day-supply limits apply cumulatively across all products. Off-label use (e.g., pre-diabetes extension of SURMOUNT-1) subject to weight management criteria if efficacy is not independent of weight loss.

verified June 5, 2026 · source: weight-management-policy-pdf

Zepbound for Osa

What Excellus BCBS requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Covered with requirements

What you need to qualify

  • Age 18 and older
  • BMI of 40 or higher
  • BMI of 35 or higher with a weight-related condition (OSA)
  • BMI of 25 or higher for patients of Asian descent
  • 3 months of a documented diet and exercise program
  • Prior trial of another GLP-1 medication (Foundayo) for at least 180 days
  • Diagnosed obstructive sleep apnea

Qualification pathways

You can qualify through any one of these.

OSA in adults with obesity — integrated into weight management criteria (Class III obesity)

All of:

  • Age ≥ 18 years
  • Diagnosis of moderate to severe obstructive sleep apnea
  • Obesity (BMI ≥ 40 kg/m²)
  • Enrolled in qualified comprehensive weight management program for ≥3 consecutive months
  • Documentation of trial and failure of Foundayo OR documented contraindication to Foundayo
  • Not used in combination with any other GIP and/or GLP-1 receptor agonist
  • Coverage criteria apply to Zepbound pens only (vials and Kwikpens not covered)

OSA in adults with obesity — integrated into weight management criteria (Class II obesity with OSA comorbidity)

All of:

  • Age ≥ 18 years
  • Diagnosis of moderate to severe obstructive sleep apnea
  • BMI 35–39.9 kg/m²
  • OSA as qualifying comorbidity
  • Enrolled in qualified comprehensive weight management program for ≥3 consecutive months
  • Documentation of trial and failure of Foundayo OR documented contraindication to Foundayo
  • Not used in combination with any other GIP and/or GLP-1 receptor agonist
  • Coverage criteria apply to Zepbound pens only (vials and Kwikpens not covered)

Documentation to bring

  • Baseline BMI and weight documentation
  • Documentation of moderate to severe obstructive sleep apnea diagnosis
  • Documentation of obesity (BMI ≥35 kg/m² with OSA as comorbidity, or BMI ≥40 kg/m²)
  • Documentation of current enrollment in qualified comprehensive weight management program for ≥3 consecutive months
  • Proof of participation in comprehensive weight management program (receipt or certificate and dietary/exercise logs)
  • Documentation of trial and failure of Foundayo OR documented contraindication to Foundayo

Quantity limits

  • 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg — 2 mL (4 pens) per 28 days; Maximum 14 twenty-eight-day supplies OR 5 eighty-four-day supplies per 365 days; first 6 fills for new starts limited to 28-day supply or less; 2.5mg strength limited to 2mL per 365 days (titration only) (84-day)

Approval and renewal

  • Initial approval: 7 months
  • Renewal: every 6 months
  • To renew, the plan looks for at least 5% weight loss from the starting weight, OSA indication uses same continuation criteria as weight management: ≥5% weight loss by 7 months at initial recertification; maintained ≥5% weight loss or continued weight loss at ongoing 6-month recertifications; BMI not less than 18.5 kg/m²; maintenance dose (5mg, 7.5mg, 10mg, 12.5mg, or 15mg) required at recertification. OSA diagnosis not re-verified at continuation, at least 17 weeks on therapy before the first renewal, and staying on a maintenance dose of at least 5 mg. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

  • Zepbound vials and Kwikpens are not a covered benefit for this indication
  • Combination with other GIP and/or GLP-1 receptor agonists not approved
  • Combination with any other weight loss drugs (Rx, OTC, or herbal) not approved
  • 2.5mg strength limited to initial 4-week titration only
  • Clinical efficacy in OSA determined to be inherently dependent on weight loss — OSA indication integrated into weight management criteria

Exceptions

  • New York: All utilization management requirements compliant with applicable New York State insurance laws and regulations

Policy note: FDA approved Zepbound for moderate to severe OSA in adults with obesity on December 20, 2024. Plan has integrated OSA indication into existing weight management criteria because clinical efficacy in OSA is determined to be inherently dependent on weight loss. No specific AHI threshold is stated — policy refers to 'moderate to severe OSA' consistent with FDA-approved indication. No PAP therapy trial requirement specified. OSA qualifies as a comorbidity for Class II obesity coverage threshold. AHI minimum not quantified in this policy document.

verified June 5, 2026 · source: weight-management-policy-pdf

ACA Marketplace

Covered with requirements

What you need to qualify

  • Age 18 and older
  • BMI of 40 or higher
  • BMI of 35 or higher with a weight-related condition (OSA)
  • BMI of 25 or higher for patients of Asian descent
  • 3 months of a documented diet and exercise program
  • Prior trial of another GLP-1 medication (Foundayo) for at least 180 days
  • Diagnosed obstructive sleep apnea

Qualification pathways

You can qualify through any one of these.

OSA in adults with obesity — integrated into weight management criteria (Class III obesity)

All of:

  • Age ≥ 18 years
  • Diagnosis of moderate to severe obstructive sleep apnea
  • Obesity (BMI ≥ 40 kg/m²)
  • Enrolled in qualified comprehensive weight management program for ≥3 consecutive months
  • Documentation of trial and failure of Foundayo OR documented contraindication to Foundayo
  • Not used in combination with any other GIP and/or GLP-1 receptor agonist
  • Coverage criteria apply to Zepbound pens only (vials and Kwikpens not covered)

OSA in adults with obesity — integrated into weight management criteria (Class II obesity with OSA comorbidity)

All of:

  • Age ≥ 18 years
  • Diagnosis of moderate to severe obstructive sleep apnea
  • BMI 35–39.9 kg/m²
  • OSA as qualifying comorbidity
  • Enrolled in qualified comprehensive weight management program for ≥3 consecutive months
  • Documentation of trial and failure of Foundayo OR documented contraindication to Foundayo
  • Not used in combination with any other GIP and/or GLP-1 receptor agonist
  • Coverage criteria apply to Zepbound pens only (vials and Kwikpens not covered)

Documentation to bring

  • Baseline BMI and weight documentation
  • Documentation of moderate to severe obstructive sleep apnea diagnosis
  • Documentation of obesity (BMI ≥35 kg/m² with OSA as comorbidity, or BMI ≥40 kg/m²)
  • Documentation of current enrollment in qualified comprehensive weight management program for ≥3 consecutive months
  • Proof of participation in comprehensive weight management program (receipt or certificate and dietary/exercise logs)
  • Documentation of trial and failure of Foundayo OR documented contraindication to Foundayo

Quantity limits

  • 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg — 2 mL (4 pens) per 28 days; Maximum 14 twenty-eight-day supplies OR 5 eighty-four-day supplies per 365 days; first 6 fills for new starts limited to 28-day supply or less; 2.5mg strength limited to 2mL per 365 days (titration only) (84-day)

Approval and renewal

  • Initial approval: 7 months
  • Renewal: every 6 months
  • To renew, the plan looks for at least 5% weight loss from the starting weight, OSA indication uses same continuation criteria as weight management: ≥5% weight loss by 7 months at initial recertification; maintained ≥5% weight loss or continued weight loss at ongoing 6-month recertifications; BMI not less than 18.5 kg/m²; maintenance dose (5mg, 7.5mg, 10mg, 12.5mg, or 15mg) required at recertification. OSA diagnosis not re-verified at continuation, at least 17 weeks on therapy before the first renewal, and staying on a maintenance dose of at least 5 mg. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

  • Zepbound vials and Kwikpens are not a covered benefit for this indication
  • Combination with other GIP and/or GLP-1 receptor agonists not approved
  • Combination with any other weight loss drugs (Rx, OTC, or herbal) not approved
  • 2.5mg strength limited to initial 4-week titration only
  • Clinical efficacy in OSA determined to be inherently dependent on weight loss — OSA indication integrated into weight management criteria

Exceptions

  • New York: All utilization management requirements compliant with applicable New York State insurance laws and regulations

Policy note: FDA approved Zepbound for moderate to severe OSA in adults with obesity on December 20, 2024. Plan has integrated OSA indication into existing weight management criteria because clinical efficacy in OSA is determined to be inherently dependent on weight loss. No specific AHI threshold is stated — policy refers to 'moderate to severe OSA' consistent with FDA-approved indication. No PAP therapy trial requirement specified. OSA qualifies as a comorbidity for Class II obesity coverage threshold. AHI minimum not quantified in this policy document.

verified June 5, 2026 · source: weight-management-policy-pdf

Why Zepbound requests get denied by Excellus BCBS

Based on what this policy asks for. Fix these before the first submission.

  1. Wrong brand for the diagnosis. Zepbound and Mounjaro are the same molecule with different approved uses; a request for Zepbound under a diagnosis that matches Mounjaro is routinely denied.
  2. BMI not documented in the chart notes (or documented without a baseline weight and date).
  3. Qualifying weight-related condition not documented with its own diagnosis code.
  4. No documented diet and exercise program.
  5. Required prior medication trials not documented.
  6. Baseline weight wasn't recorded at the start, so the required weight loss can't be shown at renewal.

Frequently asked questions

Does Excellus BCBS cover Zepbound?
Excellus BCBS covers Zepbound for weight loss with prior authorization on Employer / Commercial Insurance and ACA Marketplace.
What BMI do you need for Zepbound under Excellus BCBS?
For weight loss on Employer / Commercial Insurance plans, Excellus BCBS requires a BMI of 40 or higher, or 35 or higher with a qualifying weight-related condition. Other plan types may differ — see each plan type below.
How long does a Zepbound approval last with Excellus BCBS?
Initial approvals last 7 months, and renewals are granted in 6-month periods.
What does Excellus BCBS require to renew Zepbound?
At least 5% weight loss from the starting weight, At initial recertification (7 months): physician-verified weight loss of ≥5% of initial weight. For ongoing 6-month recertifications: must have maintained ≥5% weight loss OR continued to lose weight; current BMI must not be less than 18.5 kg/m². Patient must be utilizing maintenance dose (5mg, 7.5mg, 10mg, 12.5mg, or 15mg). For patients unable to tolerate approved maintenance doses, minimum of 5mg once weekly will be covered. Continued comprehensive weight management program enrollment required, at least 17 weeks on therapy before the first renewal, and staying on a maintenance dose of at least 5 mg.
How current is this information?
This page reflects Excellus BCBS's written policy as of its current version, last verified against the source document on June 5, 2026.

Other medications under Excellus BCBS

Zepbound coverage under other plans

All insurance plans · All medications

This page summarizes Excellus BCBS's written prior-authorization policy. It is not a guarantee of coverage; plans vary by employer and benefit design. Verify with your plan before relying on it.